Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $43.
October 04, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners (SGRY) and maintained a price target of $43, indicating confidence in the company's performance.
The reiteration of an Overweight rating and a maintained price target of $43 by a reputable analyst suggests positive sentiment and confidence in Surgery Partners' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100